Co-Founder and CEO of Biossil, an innovative applied AI drug discovery platform dedicated to developing targeted therapies for biologically defined patient sub-populations, Anthony Mouchantaf is a Lawyer and Adjunct Professor at the University of Toronto, Faculty of Law. His extensive experience includes serving as Head of RBCx Capital at the Royal Bank of Canada, Co-Founding Rthm Technologies (acquired in 2018), and working as a Venture Capital Investor at OMERS Ventures.